X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
intergroupe francophone (132) 132
index medicus (127) 127
humans (126) 126
hematology (103) 103
multiple myeloma (91) 91
oncology (82) 82
bortezomib (66) 66
stem-cell transplantation (65) 65
prognosis (63) 63
multiple myeloma - genetics (58) 58
multiple myeloma - therapy (53) 53
survival (49) 49
male (48) 48
middle aged (48) 48
aged (47) 47
multiple myeloma - drug therapy (47) 47
female (46) 46
adult (38) 38
in-situ hybridization (37) 37
multiple myeloma - pathology (36) 36
multiple myeloma - mortality (35) 35
treatment outcome (33) 33
transplantation (32) 32
intergroupe-francophone (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
chromosome aberrations (29) 29
therapy (28) 28
molecular classification (27) 27
multiple myeloma - diagnosis (27) 27
lenalidomide (26) 26
cytogenetics (25) 25
transplantation, autologous (25) 25
care and treatment (24) 24
lenalidomide plus dexamethasone (24) 24
dexamethasone (23) 23
antineoplastic agents - therapeutic use (21) 21
expression (21) 21
high-dose therapy (21) 21
thalidomide (21) 21
cancer (20) 20
thalidomide - analogs & derivatives (20) 20
aged, 80 and over (19) 19
autologous transplantation (19) 19
chemotherapy (19) 19
hematopoietic stem cell transplantation (19) 19
high-dose melphalan (19) 19
international staging system (19) 19
disease-free survival (18) 18
genetic abnormalities (18) 18
plus dexamethasone (18) 18
abnormalities (17) 17
gene expression profiling (17) 17
risk factors (17) 17
stem cell transplantation (17) 17
stem cells (17) 17
abridged index medicus (16) 16
bone-marrow-transplantation (16) 16
elderly-patients (16) 16
multiple-myeloma (16) 16
research (16) 16
survival analysis (16) 16
genetic aspects (15) 15
hematology, oncology and palliative medicine (15) 15
hematopoietic stem cell transplantation - methods (15) 15
low-dose dexamethasone (15) 15
melphalan (15) 15
retrospective studies (15) 15
article (14) 14
lenalidomide maintenance (14) 14
myeloma (14) 14
randomized-trial (14) 14
thalidomide - therapeutic use (14) 14
carfilzomib (13) 13
conditioning regimen (13) 13
diagnosed multiple-myeloma (13) 13
health aspects (13) 13
immunology (13) 13
in situ hybridization, fluorescence (13) 13
prognostic-factor (13) 13
combined modality therapy (12) 12
follow-up studies (12) 12
leukemia (12) 12
minimal residual disease (12) 12
monoclonal gammopathy (12) 12
staging system (12) 12
analysis (11) 11
gene expression (11) 11
induction therapy (11) 11
recurrence (11) 11
working group (11) 11
200 mg/m (10) 10
consolidation therapy (10) 10
dexamethasone - administration & dosage (10) 10
gene-expression (10) 10
medicine & public health (10) 10
pomalidomide (10) 10
term-follow-up (10) 10
cyclophosphamide (9) 9
gene expression regulation, neoplastic (9) 9
genetic aberrations (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 22, pp. 2401 - 2409
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring... 
INTERGROUPE FRANCOPHONE | IMPACT | CARFILZOMIB | RESPONSE CRITERIA | T(11/14)(Q13,Q32) | CHRONIC LYMPHOCYTIC-LEUKEMIA | DARATUMUMAB MONOTHERAPY | OPEN-LABEL | BORTEZOMIB | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Life Sciences | Cancer
Journal Article
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 02/2017, Volume 15, Issue 2, pp. 230 - 230
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal... 
SINGLE-AGENT CARFILZOMIB | INTERGROUPE FRANCOPHONE | DONOR LYMPHOCYTE INFUSIONS | INDUCTION THERAPY | ONCOLOGY | BORTEZOMIB PLUS DEXAMETHASONE | HIGH-DOSE THERAPY | INTERNATIONAL STAGING SYSTEM | TERM-FOLLOW-UP | STEM-CELL TRANSPLANTATION | LENALIDOMIDE MAINTENANCE
Journal Article
LEUKEMIA, ISSN 0887-6924, 02/2018, Volume 32, Issue 2, pp. 383 - 390
The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial... 
DIAGNOSED MULTIPLE-MYELOMA | INTERGROUPE FRANCOPHONE | STAGING SYSTEM | MAINTENANCE TREATMENT | PLUS DEXAMETHASONE | ONCOLOGY | RANDOMIZED-TRIAL | 2ND PRIMARY MALIGNANCIES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DEXAMETHASONE COMBINATION | DELETION 17P
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1770 - 1781
Journal Article
BONE MARROW TRANSPLANTATION, ISSN 0268-3369, 02/2019, Volume 54, Issue 2, pp. 293 - 299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m(2) (MEL 200). Higher doses of... 
MULTICENTER | RANDOMIZED-TRIAL | BORTEZOMIB | IMMUNOLOGY | CONDITIONING REGIMEN | CHEMOTHERAPY | TRANSPLANTATION | INTERGROUPE FRANCOPHONE | MAINTENANCE | ONCOLOGY | LENALIDOMIDE | HIGH-DOSE MELPHALAN | MARROW-TRANSPLANTATION | HEMATOLOGY
Journal Article
Journal Article